Ionis shares plummet as GSK scraps heart drug trial plans

27 May 2016
ionis-big

Shares in Ionis Pharmaceuticals (Nasdaq: IONS) have plunged 40% after GlaxoSmithKline (LSE: GSK) scrapped plans to test the company’s  IONIS-TTR heart drug in late-stage trials.

The decision is a serious blow to the California-based company which saw more than $900 million wiped from its market value as a result. It comes two months after the US Food and Drug Administration put a clinical hold on the trial testing the drug, citing safety concerns.

IONIS-TTR is being developed for the treatment of transthyretin cardiomyopathy, a rare and fatal disease associated with progressive heart failure.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical